CMLase: An Aging Eraser? The Science Behind the Hype

What if the next big idea in anti-aging is not adding more collagen, but repairing the collagen you already have?

That is the question behind CMLase, an engineered enzyme from Revel Pharmaceuticals. In laboratory experiments, it removed a stubborn chemical modification from proteins in donated human tissue. The results are compelling enough to deserve attention. They are also easy to turn into a headline that promises far more than the science shows.

The headline worth sharing: scientists repaired one kind of age-related protein damage in the lab. They did not make a person younger. CMLase is experimental, not an approved treatment, and Body Tonic RX does not offer it.

Why everyone is talking about CMLase

The research, published in Nature Communications in July 2026, addresses a problem that has frustrated aging researchers for decades: some chemical changes build up on long-lived proteins and do not simply disappear with normal maintenance.

Revel's team engineered an enzyme to reverse one of those changes. Collaborators included scientists from Calico and the University of Colorado Anschutz Medical Campus. Their experiments provide a proof of concept for molecular repair, not clinical proof of rejuvenation.

The damage hiding in long-lived proteins

Proteins can acquire chemical modifications through reactions involving sugars and reactive products of sugar or fat chemistry. Some of these modifications are called advanced glycation end products, or AGEs. One common example is Nε-carboxymethyl-lysine, shortened to CML.

On proteins that are replaced quickly, damage may leave when the protein is replaced. On proteins that last much longer, including some structural proteins in skin and arteries and proteins in the eye's lens, modifications can accumulate over time.

CML is one specific mark within that larger picture. It is not a synonym for all aging damage. It is also not the same thing as glucosepane, a different AGE that forms crosslinks between proteins. Removing CML does not establish that an enzyme breaks those crosslinks or restores tissue elasticity.

What does the enzyme actually do?

CMLase targets the CML modification on lysine, an amino acid within proteins. It oxidizes the modification and restores native lysine rather than cutting apart the whole protein.

Think of the goal as repairing a damaged part rather than throwing away the entire structure. That is an analogy, not a claim that tissue becomes new. In the reported experiments, the team found evidence of chemical repair while preserving the underlying model proteins.

The enzyme was engineered from a bacterial glycine oxidase scaffold using directed evolution across more than 500 million variants. The resulting variant, CrGO-897, is the enzyme called CMLase. It is an engineered protein catalyst, not a skincare ingredient or an interchangeable alternative to peptide treatments.

The numbers are striking. Here is what they measure.

• More than 70% reduction in CML staining in arterial tissue sections from a 75-year-old donor.
• More than 55% reduction in CML staining in aged skin tissue sections.
• CML staining in treated aged skin below the level seen in a 31-year-old skin comparison. This is a comparison of one laboratory marker, not a measurement of the skin's biological age or appearance.

These findings came from donated tissue studied outside the body, including thin, fixed tissue sections and prepared lens proteins. The tissue experiments were not treatments performed on living volunteers. They did not measure wrinkle reduction, firmer skin, better vision, improved circulation, or extra years of life.

A 55% reduction in a marker is not 55% less aging. That distinction belongs beside the exciting numbers, not buried in the fine print.

Could protein repair change the anti-aging industry?

Potentially, but the opportunity is a research direction rather than a product launch. If scientists can make targeted protein repair safe and effective in living tissue, it could add a different approach to a field that often focuses on prevention, appearance, or stimulating new tissue production.

Skin research could look beyond making more collagen

The prospect of repairing chemical damage on existing proteins raises a new question: can improving protein chemistry eventually improve tissue function? CMLase has not answered that yet. Skin texture, elasticity, and visible results would need their own studies in people.

Longevity research could focus on repair, not just markers

CML can engage RAGE, a receptor associated with inflammatory signaling. That gives researchers a reason to investigate whether reducing CML might affect disease-related processes. The study does not establish that CMLase reduces inflammation or prevents age-related disease in people.

The engineering platform may matter as much as this enzyme

The ability to build an enzyme for a previously difficult chemical reaction suggests a way to investigate other forms of protein damage. Glucosepane is one possible future target discussed by the researchers. CMLase itself has not been shown to remove glucosepane. Each new target would require a separate enzyme-development effort and its own evidence.

The standard for marketing should rise, too

If the science advances, the industry will need to distinguish laboratory marker changes from meaningful patient benefits. A credible future treatment would need data on safety, delivery, dose, duration, and actual outcomes. A dramatic headline cannot supply any of those.

The hurdles between a lab finding and an appointment

The paper's authors identify important unanswered questions:

• Getting into living tissue: thin laboratory sections make damage easier to reach. An enzyme may behave differently inside dense, intact tissue.
• Restoring function: removing CML does not yet prove recovery of tissue mechanics or a reduction in harmful signaling.
• Immune reactions: an enzyme with a bacterial origin requires careful evaluation, especially if repeat dosing is considered.
• Reaction byproducts: the chemistry produces hydrogen peroxide and glyoxylate. Their effects and handling need evaluation in a real treatment setting.
• Clinical evidence: researchers still need to establish an appropriate delivery method, safety, dosing, and benefits in people.

There is no established clinic price, approved treatment schedule, or reliable availability date to share. Revel says it is working toward first human studies. That is not a promise of approval or a release date.

Can you buy CMLase or book it now?

No approved CMLase treatment is available. Revel states that it does not sell CMLase or offer it through a clinic, supplement, or skincare product. Body Tonic RX does not offer it either.

A product advertised as an aging enzyme, a glycation supplement, or an anti-aging peptide is not automatically CMLase and does not inherit this study's findings. Do not use research materials on yourself or treat a social-media offer as evidence of safety.

What should you do while the science develops?

You do not need to wait for an experimental enzyme to care for your skin and health. Sun protection, avoiding smoking, regular activity, sleep, and appropriate medical care remain sensible foundations. If you want to discuss current options for your skin, our Aesthetics page outlines the treatments we actually offer. Our Wellness page covers our current care options.

Those services are not CMLase and should not be presented as producing the same molecular repair. An assessment should match a treatment to your goals, history, and the evidence for that treatment.

The real story is more interesting than the hype

CMLase does not prove that aging has been solved. It shows that one chemical modification once viewed as stubbornly irreversible can be repaired under laboratory conditions.

That is enough to make this worth watching. If the work moves from chemical repair to safe, meaningful benefits in living people, the implications could reach well beyond cosmetic care. For now, the honest headline is also the most useful one: a new route to protein repair has opened in research, and the clinical story is still unwritten.

Sources and further reading

1. Revel Pharmaceuticals: CMLase. Developer's overview, tissue findings, and availability statement.
2. Reversal of protein chemical aging by enzymatic deglycation. Nature Communications, July 14, 2026. DOI: 10.1038/s41467-026-75141-2. See the tissue experiments and Discussion for limitations.

Sources reviewed November 14, 2026. Research and regulatory status may change. This article is educational commentary, not an endorsement of a CMLase product.